Social StressPhase 2/3NCT02793193
Effect of Probiotics on Central Nervous System Functions in Humans
A Phase 2/3 study testing Probiotic and Antibiotic in people with Social Stress, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
The gut-brain axis is described as being important in both, gut functions and central nervous system (CNS) functions. The microbiota in the gut plays an important role in this axis through neural, immune and endocrine systems. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Social Stress
- What is being tested?
- Probiotic and Antibiotic
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- 1 siteGermany
- Study dates
- Jul 2016to Jan 2018
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male and female volunteers aged 18 to 50 years.
- Signed informed consent. Written informed consent will need to be obtained from all participants, and the protocol will be submitted to the Ethics Board of the Medical School for approval,
- Participant is willing to comply with the study restrictions.
- Participant has been a non-smoker for at least 3 months.
- Participants with body mass index 18-30.
Who cannot join
- Participants are current smokers,
- Participants have chronic allergies,
- Participants are unwilling to discontinue the consumption of probiotic- and prebiotic-containing foods or potentially immune-enhancing dietary supplements (i.e. prebiotics, probiotics, Echinacea, fish oil and vitamin E (>400 % of the RDA or .60 mg/d)),
- Participants received an immune-suppressing intervention or have an immunosuppressive illness within the last year,
- Participants have a psychiatric disorder (eg. depression, anxiety, dysthymia, panic disorder, disorder of mania or bipolar disorder, phobia, post-traumatic stress disorder, substance abuse, eating disorder) (only for recruiting healthy volunteers).
- Participants received antibiotic therapy within the last 2 months of their study start date.
- Participants have non-removable metal parts in the body such as: pacemaker, artificial heart valves, metal prostheses, implanted magnetic metal parts (screws), spiral, metal fragments / shrapnel, fixed braces, acupuncture needle, insulin pump, tattoos, eye shadow. Also, people with agoraphobia will be excluded.
- Patients who do not meet the diagnosis criteria of IBS based on Rome I, II, or III (only for recruiting patients).
Trial locations and contacts
1 site in 1 country.
About this study
The gut-brain axis is described as being important in both, gut functions and central nervous system (CNS) functions. The microbiota in the gut plays an important role in this axis through neural, immune and endocrine systems. Previous studies have found altered gut microbiota (GM) composition could change the CNS functions in animals and humans. Probiotics were shown having positive effect on improving stress response in animals and stress related psychiatry in humans. The current study will investigate if probiotics can improve response to social stress in healthy participants and patients with irritable bowel syndrome (IBS), which is a stress-related disease, and whether this probiotic action can be counteracted by the locally acting antibiotic, Rifaximin. The investigators will use the Cyberball paradigram to induce social stress and magnetoencephalography (MEG) to record neural responses related to the social stress. The administration of the probiotics will be a new strategy for both the mental health management and treatment of gastrointestinal (GI) disorders in the future.
Read the detailed description
Understanding the neural mechanisms underlying the experience of social stress may help to prevent the development of IBS and to help people to maintain their mental health. Social distress has been examined with the Cyberball paradigm in developing peers and children with autism spectrum disorders, people with social anxiety disorder and with borderline personality disorder. These studies provided researchers the clinical evidence and validity of the paradigm in patients . Here the investigators will examine the neural response of healthy volunteers to acute stress induced by the Cyberball game and if acute intervention with probiotics for 4 weeks can alleviate the stress response. The study will be firstly conducted on healthy volunteers whose GM will be disturbed by an antibiotic Rifaximin as to simulate IBS patients, to see their neural response to the social exclusion (Study 1). The second study will be conducted as a clinical trial in healthy volunteers to investigate the effect of the probiotic Bifidobacterium longum 1714 (Study 2).
Study 1 \& 2 will be a randomized, double blind, double dummy design, during which the participants will visit the laboratory for 2 times (M1, M2,): measurement at baseline and after intervention. Intervention period lasts for 1 week in study 1 and 4 weeks in study 2.
In study 1, Group 1 will take Rifaximin for 1 week Group 2 will take Placebo for 1 week
In study 2, Group 1 will take B.longum 1714 for 4 weeks Group 2 will take Placebo for for 4 weeks
Participants will be not allowed to eat certain kinds of food. As mentioned in the exclusion criteria, participants will not eat probiotic/prebiotic containing food supplements, or potentially immune-enhancing dietary supplements either. The food to be avoided will be summarized on a list of probiotic/prebiotic containing food. Also, participants will be asked to record the food they take on each day during the intervention, by taking photos. Nutritional information about the food taken by the participants will be analyzed by using an online tool http://nutritiondata.self.com/.
Before the intervention period, each participant will need to complete questionnaires including a demographic questionnaire, the Patient Health Questionnaire (PHQ) and the Hospital Anxiety and Depression Scale (HADS). The PHQ is for excluding those healthy participants who suffer from psychiatry disorder(s) and for further analysis. The HADS, which will also be completed after each intervention period, aims to study the effect of the probiotic on anxiety and depression level in healthy participants and especially in IBS patients. Also, participants will receive a daily online questionnaire via email, including the Positive Affect and Negative Affect Scales, and questions about their level of stress, consumption of the study capsules, hours of sleep, IBS symptom and quality of life (QoL) (the last two are only for patients), etc. Through questionnaires, the investigators will record menstruation information of female participants for controlling confounders. Also, gender and age between healthy and patient groups will be matched as much as possible, since these factors could have an effect on the GM composition and the CNS functions.
Stool samples will be collected on the day participants come to a lab visit for measurements. The stool sample should be as fresh as possible, ideally collected in the morning of the visiting day. Fresh samples will be stored in RNA synthesis stabilization buffer at the time of collection. A centrifuged fecal pellet will be stored at -80°.
During the Magnetoencephalography measuring, before the Cyberball game, there will be a resting state session for 5 minutes. In this session participants will be studied in supine position. Participants will be instructed to move as little as possible and remain awake, while keeping their eyes closed. After the resting state recording the Cyberball game will start. The task of the game will be projected on a screen and participants will be asked to fixate the screen and hold a response box to get ready for the task. Magnetic fields will be measured with a 275-channel whole head magnetometer at a sampling rate of 1200 Hz. In order to overlay the brain activity derived from MEG on anatomical scans, a high-resolution (1 mm, isotropic) T1-weighted structural MR image will be acquired with an MPRAGE sequence with a 3-T MR scanner (University Hospital Tübingen, Tübingen, Germany).
7 participants will be needed in each experimental group in study 1, resulting in at least 14 in study 1. 20 participants will be needed in each experimental group in study 2, resulting in at least 40 in study 2. The recruitment of participants will be organized by the MEG center under the responsibility of Prof. Dr. Christoph Braun. The study will be announced on black boards in the Tübingen University Clinic and the campus of the University. Further announcements will be done via the University mailing list and the local newspaper. Each participant will be provided with detailed information about the aims of the investigation, the tasks and measurements. Participants will be informed about the possibility to cancel the examination at any time without cause or prejudice for her person. Investigation will be carried out only when written consent from the participants is obtained.
- Conditions
- Social Stress
- Being tested
- Probiotic, Placebo for antibiotic, Antibiotic, Placebo for probiotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ProbioticDietary supplement
Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
Placebo for antibioticDietary supplement
The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
AntibioticDrug
Antibiotic Xifaxan ® will be 200mg per tablet
Placebo for probioticDietary supplement
The placebo identical-looking to the probiotic B.longum 1714
| Study group | Role | What they receive |
|---|---|---|
| Active (rifaximin/B.longum 1714) | Experimental | Not described Receives: Dietary Supplement: Probiotic; Drug: Antibiotic |
| Placebo | Experimental | Not described Receives: Dietary Supplement: Placebo for antibiotic; Dietary Supplement: Placebo for probiotic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neural response to social stress measured by Magnetoencephalography
Measured: 8 weeks
Secondary outcomes (6)
Bacterial population levels in faecal samples
Measured: 8 weeks
Cortisol levels in blood samples
Measured: 8 weeks
Tryptophan levels in blood samples
Measured: 8 weeks
Score of the Hospital Anxiety and Depression Scale (HADS)
the RAND 36-Item Healthy Survey
Measured: 8 weeks
Scores of the Positive and Negative Affect Scales (PANAS)
Measured: 8 weeks
Scores of the RAND 36-Item Healthy Survey
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2016 (estimated)
- Study startJul 2016
- Primary completionJan 2018
- Study completionJan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Social StressStudies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paul Enck, Prof. Dr., Principal investigator, Department of Internal Medicine VI: Psychosomatic Medicine and Psychotherapy, University of Tuebingen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02793193
- Sponsor's protocol ID
- PITN-GA-2013-607652
- Status last verified
- May 2016
- First submitted
- 25 May 2016
- Last updated
- 2 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Publications
Wang H, Braun C, Enck P. Effects of Rifaximin on Central Responses to Social Stress-a Pilot Experiment. Neurotherapeutics. 2018 Jul;15(3):807-818. doi: 10.1007/s13311-018-0627-2.
PubMed 29713909
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Probiotics on Central Nervous System Functions in Humans
- ClinicalTrials.gov ID
- NCT02793193
- Acronym / sponsor ID
- PITN-GA-2013-607652
- Conditions
- Social Stress
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Study start
- Jul 2016
- Primary completion
- Jan 2018 (actual)
- Study completion
- Jan 2018 (actual)
- First posted
- 8 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The gut-brain axis is described as being important in both, gut functions and central nervous system (CNS) functions. The microbiota in the gut plays an important role in this axis through neural, immune and endocrine systems. Previous studies have found altered gut microbiota (GM) composition could change the CNS functions in animals and humans. Probiotics were shown having positive effect on improving stress response in animals and stress related psychiatry in humans. The current study will investigate if probiotics can improve response to social stress in healthy participants and patients with irritable bowel syndrome (IBS), which is a stress-related disease, and whether this probiotic action can be counteracted by the locally acting antibiotic, Rifaximin. The investigators will use the Cyberball paradigram to induce social stress and magnetoencephalography (MEG) to record neural responses related to the social stress. The administration of the probiotics will be a new strategy for both the mental health management and treatment of gastrointestinal (GI) disorders in the future.
Detailed description
Understanding the neural mechanisms underlying the experience of social stress may help to prevent the development of IBS and to help people to maintain their mental health. Social distress has been examined with the Cyberball paradigm in developing peers and children with autism spectrum disorders, people with social anxiety disorder and with borderline personality disorder. These studies provided researchers the clinical evidence and validity of the paradigm in patients . Here the investigators will examine the neural response of healthy volunteers to acute stress induced by the Cyberball game and if acute intervention with probiotics for 4 weeks can alleviate the stress response. The study will be firstly conducted on healthy volunteers whose GM will be disturbed by an antibiotic Rifaximin as to simulate IBS patients, to see their neural response to the social exclusion (Study 1). The second study will be conducted as a clinical trial in healthy volunteers to investigate the effect of the probiotic Bifidobacterium longum 1714 (Study 2).
Study 1 \& 2 will be a randomized, double blind, double dummy design, during which the participants will visit the laboratory for 2 times (M1, M2,): measurement at baseline and after intervention. Intervention period lasts for 1 week in study 1 and 4 weeks in study 2.
In study 1, Group 1 will take Rifaximin for 1 week Group 2 will take Placebo for 1 week
In study 2, Group 1 will take B.longum 1714 for 4 weeks Group 2 will take Placebo for for 4 weeks
Participants will be not allowed to eat certain kinds of food. As mentioned in the exclusion criteria, participants will not eat probiotic/prebiotic containing food supplements, or potentially immune-enhancing dietary supplements either. The food to be avoided will be summarized on a list of probiotic/prebiotic containing food. Also, participants will be asked to record the food they take on each day during the intervention, by taking photos. Nutritional information about the food taken by the participants will be analyzed by using an online tool http://nutritiondata.self.com/.
Before the intervention period, each participant will need to complete questionnaires including a demographic questionnaire, the Patient Health Questionnaire (PHQ) and the Hospital Anxiety and Depression Scale (HADS). The PHQ is for excluding those healthy participants who suffer from psychiatry disorder(s) and for further analysis. The HADS, which will also be completed after each intervention period, aims to study the effect of the probiotic on anxiety and depression level in healthy participants and especially in IBS patients. Also, participants will receive a daily online questionnaire via email, including the Positive Affect and Negative Affect Scales, and questions about their level of stress, consumption of the study capsules, hours of sleep, IBS symptom and quality of life (QoL) (the last two are only for patients), etc. Through questionnaires, the investigators will record menstruation information of female participants for controlling confounders. Also, gender and age between healthy and patient groups will be matched as much as possible, since these factors could have an effect on the GM composition and the CNS functions.
Stool samples will be collected on the day participants come to a lab visit for measurements. The stool sample should be as fresh as possible, ideally collected in the morning of the visiting day. Fresh samples will be stored in RNA synthesis stabilization buffer at the time of collection. A centrifuged fecal pellet will be stored at -80°.
During the Magnetoencephalography measuring, before the Cyberball game, there will be a resting state session for 5 minutes. In this session participants will be studied in supine position. Participants will be instructed to move as little as possible and remain awake, while keeping their eyes closed. After the resting state recording the Cyberball game will start. The task of the game will be projected on a screen and participants will be asked to fixate the screen and hold a response box to get ready for the task. Magnetic fields will be measured with a 275-channel whole head magnetometer at a sampling rate of 1200 Hz. In order to overlay the brain activity derived from MEG on anatomical scans, a high-resolution (1 mm, isotropic) T1-weighted structural MR image will be acquired with an MPRAGE sequence with a 3-T MR scanner (University Hospital Tübingen, Tübingen, Germany).
7 participants will be needed in each experimental group in study 1, resulting in at least 14 in study 1. 20 participants will be needed in each experimental group in study 2, resulting in at least 40 in study 2. The recruitment of participants will be organized by the MEG center under the responsibility of Prof. Dr. Christoph Braun. The study will be announced on black boards in the Tübingen University Clinic and the campus of the University. Further announcements will be done via the University mailing list and the local newspaper. Each participant will be provided with detailed information about the aims of the investigation, the tasks and measurements. Participants will be informed about the possibility to cancel the examination at any time without cause or prejudice for her person. Investigation will be carried out only when written consent from the participants is obtained.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active (rifaximin/B.longum 1714) | Experimental | Dietary Supplement: Probiotic, Drug: Antibiotic |
| Placebo | Experimental | Dietary Supplement: Placebo for antibiotic, Dietary Supplement: Placebo for probiotic |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male and female volunteers aged 18 to 50 years.
- Signed informed consent. Written informed consent will need to be obtained from all participants, and the protocol will be submitted to the Ethics Board of the Medical School for approval,
- Participant is willing to comply with the study restrictions.
- Participant has been a non-smoker for at least 3 months.
- Participants with body mass index 18-30.
Key exclusion criteria (8 listed)
- Participants are current smokers,
- Participants have chronic allergies,
- Participants are unwilling to discontinue the consumption of probiotic- and prebiotic-containing foods or potentially immune-enhancing dietary supplements (i.e. prebiotics, probiotics, Echinacea, fish oil and vitamin E (>400 % of the RDA or .60 mg/d)),
- Participants received an immune-suppressing intervention or have an immunosuppressive illness within the last year,
- Participants have a psychiatric disorder (eg. depression, anxiety, dysthymia, panic disorder, disorder of mania or bipolar disorder, phobia, post-traumatic stress disorder, substance abuse, eating disorder) (only for recruiting healthy volunteers).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ProbioticProbiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU | Dietary supplement | Active (rifaximin/B.longum 1714) |
| Placebo for antibioticThe placebo supplementation is identical-looking to the antibiotic Xifaxan ® | Dietary supplement | Placebo |
| AntibioticAntibiotic Xifaxan ® will be 200mg per tablet | Drug | Active (rifaximin/B.longum 1714) |
| Placebo for probioticThe placebo identical-looking to the probiotic B.longum 1714 | Dietary supplement | Placebo |
Primary outcome
Neural response to social stress measured by Magnetoencephalography
Time frame: 8 weeks
6 secondary outcomes
Bacterial population levels in faecal samples
Time frame: 8 weeks
Cortisol levels in blood samples
Time frame: 8 weeks
Tryptophan levels in blood samples
Time frame: 8 weeks
Score of the Hospital Anxiety and Depression Scale (HADS)
Time frame: 8 weeks
Scores of the Positive and Negative Affect Scales (PANAS)
Time frame: 8 weeks
Scores of the RAND 36-Item Healthy Survey
Time frame: 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2020.
- Derived from this study: PubMed 29713909Wang H, Braun C, Enck P. Effects of Rifaximin on Central Responses to Social Stress-a Pilot Experiment. Neurotherapeutics. 2018 Jul;15(3):807-818. doi: 10.1007/s13311-018-0627-2.
- Individual participant dataSharing planned: Yes
Related trials for Social Stress
Recruiting
Bonding Before Birth: A mHealth Intervention for First-time Expectant Couples
Anxiety, Pregnancy
Active, not recruiting
Economic Empowerment and Health Promotion of Uganda Grandmother-caregivers.
Financial Burden, Health Behavior
Not yet recruiting
A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement
Memory Disorders, Mild Cognitive Impairment
Active, not recruiting
Self-Help Plus (SH+) for Stress Reduction in Social Service Workers: A Pilot RCT
Stress, Psychological, Occupational, Stress, Psychological
Recruiting
Trauma-Informed Yoga Intervention in Young Women
Trauma, Young Adult Females
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paul Enck, Prof. Dr. principal investigator
Department of Internal Medicine VI: Psychosomatic Medicine and Psychotherapy, University of Tuebingen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Probiotic and Antibiotic in people with Social Stress, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neural response to social stress measured by Magnetoencephalography (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02793193, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2020.